PL365779A1 - Kombinacja inhibitorów FBP-azy i środków przeciwcukrzycowych przydatna do leczenia cukrzycy - Google Patents

Kombinacja inhibitorów FBP-azy i środków przeciwcukrzycowych przydatna do leczenia cukrzycy

Info

Publication number
PL365779A1
PL365779A1 PL01365779A PL36577901A PL365779A1 PL 365779 A1 PL365779 A1 PL 365779A1 PL 01365779 A PL01365779 A PL 01365779A PL 36577901 A PL36577901 A PL 36577901A PL 365779 A1 PL365779 A1 PL 365779A1
Authority
PL
Poland
Prior art keywords
diabetes
treatment
combination
agents useful
antidiabetic agents
Prior art date
Application number
PL01365779A
Other languages
English (en)
Inventor
Poelje Paul D. Van
Mark D. Erion
Toshihiko Fujiwara
Original Assignee
Metabasis Therapeutics, Inc.
Sankyo Company, Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabasis Therapeutics, Inc., Sankyo Company, Limited filed Critical Metabasis Therapeutics, Inc.
Publication of PL365779A1 publication Critical patent/PL365779A1/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL01365779A 2000-07-06 2001-07-05 Kombinacja inhibitorów FBP-azy i środków przeciwcukrzycowych przydatna do leczenia cukrzycy PL365779A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21653100P 2000-07-06 2000-07-06

Publications (1)

Publication Number Publication Date
PL365779A1 true PL365779A1 (pl) 2005-01-10

Family

ID=22807416

Family Applications (1)

Application Number Title Priority Date Filing Date
PL01365779A PL365779A1 (pl) 2000-07-06 2001-07-05 Kombinacja inhibitorów FBP-azy i środków przeciwcukrzycowych przydatna do leczenia cukrzycy

Country Status (18)

Country Link
EP (1) EP1372660A2 (pl)
JP (1) JP2004508297A (pl)
KR (1) KR100854851B1 (pl)
CN (2) CN100396283C (pl)
AU (2) AU7327101A (pl)
BR (1) BR0112212A (pl)
CA (1) CA2412142A1 (pl)
CZ (1) CZ20035A3 (pl)
HU (1) HUP0301830A3 (pl)
IL (2) IL153513A0 (pl)
MX (1) MXPA02012713A (pl)
NO (1) NO20030034L (pl)
NZ (1) NZ523227A (pl)
PL (1) PL365779A1 (pl)
RU (1) RU2328308C2 (pl)
SK (1) SK62003A3 (pl)
WO (1) WO2002003978A2 (pl)
ZA (1) ZA200300044B (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
AU6452098A (en) 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
ATE246197T1 (de) 1998-09-09 2003-08-15 Metabasis Therapeutics Inc Neue heteroaromatische fructose 1,6- bisphosphatase inhibitoren
US6919322B2 (en) 2000-03-08 2005-07-19 Metabasis Therapeutics, Inc. Phenyl Phosphonate Fructose-1,6-Bisphosphatase Inhibitors
US7563774B2 (en) 2000-06-29 2009-07-21 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
KR100989647B1 (ko) 2001-09-24 2010-10-26 오레곤 헬스 앤드 사이언스 유니버시티 식습관의 변화
EP1474163A2 (en) 2002-01-10 2004-11-10 Imperial College Innovations Limited Modification of feeding behavior
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
CA2551611C (en) 2003-12-26 2013-06-25 Kyowa Kirin Co., Ltd. Thiazole derivatives for treating or preventing parkinson's disease
JP2008510018A (ja) * 2004-08-18 2008-04-03 メタバシス・セラピューティクス・インコーポレイテッド フルクトース−1,6−ビスホスファターゼの新規チアゾール阻害物質
WO2006064744A1 (ja) * 2004-12-13 2006-06-22 Daiichi Sankyo Company, Limited 糖尿病の治療のための医薬組成物
TW200738245A (en) * 2005-08-22 2007-10-16 Sankyo Co Pharmaceutical composition containing FBPase inhibitor
WO2007129522A1 (ja) * 2006-04-10 2007-11-15 Daiichi Sankyo Company, Limited 乾式製造法製剤
WO2008063842A2 (en) 2006-11-02 2008-05-29 Aestus Therapeutics, Inc. Methods of treating neuropathic pain with agonists of ppar-gamma
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
CN103665043B (zh) 2012-08-30 2017-11-10 江苏豪森药业集团有限公司 一种替诺福韦前药及其在医药上的应用
TWI606848B (zh) * 2012-10-08 2017-12-01 Lg生命科學股份有限公司 包含格米列汀與美氟明的組合藥物及其製備方法
CN104788350A (zh) * 2014-01-22 2015-07-22 天津大学 一种通过快速冷却结晶法获得甲糖宁药用优势晶型的方法
CN106831437B (zh) * 2016-02-03 2019-06-21 华中师范大学 含硝基乙烯基的酯类化合物及其制备方法和应用
CN114907285B (zh) * 2021-02-10 2023-09-22 华中师范大学 酰化糖精类化合物及其制备方法和应用、降血糖药物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0427799B1 (en) * 1989-01-24 1994-11-30 Gensia, Inc. Method and compounds for aica riboside delivery and for lowering blood glucose
US6054587A (en) * 1997-03-07 2000-04-25 Metabasis Therapeutics, Inc. Indole and azaindole inhibitors of fructose-1,6-bisphosphatase
AU6452098A (en) * 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
DE69819311T2 (de) * 1997-03-07 2004-07-29 Metabasis Therapeutics Inc., San Diego Neue benzimidazol inhibitoren der fructose-1,6-bisphosphatase
WO1999047549A1 (en) * 1998-03-16 1999-09-23 Ontogen Corporation PIPERAZINES AS INHIBITORS OF FRUCTOSE-1,6-BISPHOSPHATASE (FBPase)
ATE246197T1 (de) * 1998-09-09 2003-08-15 Metabasis Therapeutics Inc Neue heteroaromatische fructose 1,6- bisphosphatase inhibitoren
IL143569A0 (en) * 1998-12-24 2002-04-21 Metabasis Therapeutics Inc A combination of fbpase inhibitors and insulin sensitizers for the treatment of diabetes
PT1741446E (pt) * 2000-01-21 2008-05-09 Novartis Pharma Ag Combinações incluindo inibidores da dipeptidilpeptidase-iv e agentes anti-diabéticos
GB0015627D0 (en) * 2000-06-26 2000-08-16 Rademacher Group Limited Phosphoglycan messengers and their medical uses

Also Published As

Publication number Publication date
WO2002003978A3 (en) 2003-10-16
SK62003A3 (en) 2003-09-11
IL153513A (en) 2014-07-31
AU7327101A (en) 2002-01-21
NZ523227A (en) 2005-04-29
JP2004508297A (ja) 2004-03-18
NO20030034L (no) 2003-03-05
CA2412142A1 (en) 2002-01-17
IL153513A0 (en) 2003-07-06
CN101301294A (zh) 2008-11-12
CN1599612A (zh) 2005-03-23
MXPA02012713A (es) 2004-09-10
HUP0301830A3 (en) 2007-10-29
AU2001273271B2 (en) 2006-01-05
KR100854851B1 (ko) 2008-08-27
EP1372660A2 (en) 2004-01-02
BR0112212A (pt) 2003-12-30
CN100396283C (zh) 2008-06-25
ZA200300044B (en) 2004-05-06
NO20030034D0 (no) 2003-01-03
WO2002003978A2 (en) 2002-01-17
RU2328308C2 (ru) 2008-07-10
KR20030031952A (ko) 2003-04-23
CZ20035A3 (cs) 2003-05-14
HUP0301830A2 (hu) 2003-11-28

Similar Documents

Publication Publication Date Title
AU7327101A (en) A combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes
HUP0302950A3 (en) Synergistic herbicidal composition and a process for its use
IL153529A0 (en) Combinations of dipeptidyl peptidase iv inhibitors and other antidiabetic agents for the treatment of diabetes mellitus
EP1423120A4 (en) 2H-PHTALAZINE-1-ONES AND METHODS OF USE THEREOF
GB9900416D0 (en) Inhibitors
HUP0301083A3 (en) Synergistical herbicide composition and use thereof
GB0025782D0 (en) Use of inhibitors
PL364904A1 (pl) Tiohydantoiny i ich zastosowanie w leczeniu cukrzycy
PL373301A1 (pl) Inhibitory fosfodiesterazy 4
HUP0402506A3 (en) A combination of fbpase inhibitors and insulin sensitizers for the treatment of diabetes
EP1337255A4 (en) USE OF P38 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY COUGH
GB2361223B (en) Climbing appliance for roping-up and roping-down operations
AU2001261544A1 (en) Metal surface treatment agent
GB0105613D0 (en) Pharmaceutically effective compounds and their use
EP1153022A4 (en) PROTEASE INHIBITORS
HUP0204106A3 (en) Calcilytic compounds and process for their use
GB0202187D0 (en) "Inhibitors"
AUPQ582400A0 (en) A method of treatment and agents for use therein
AU2001264273A1 (en) Amide compounds and use thereof
AU2001269496A1 (en) Surface treating agent for metal member
GB0114572D0 (en) A method for the treatment of textile surfaces and compositions for use therein
GB0007530D0 (en) Trityl-type compounds and their use
HK1062634A (en) A combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes
HUP0302212A3 (en) Fungicidal mixture based on amide compounds and its use
HUP0402141A3 (en) Herbicidal composition and process for its use

Legal Events

Date Code Title Description
DISC Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications)